Literature DB >> 24308158

Inhibition of tumor growth and alteration of associated macrophage cell type by an HO-1 inhibitor in breast carcinoma-bearing mice.

Rui Deng1, Shi-Min Wang, Tao Yin, Ting-Hong Ye, Guo-Bo Shen, Ling Li, Jing-Yi Zhao, Ya-Xiong Sang, Xiao-Gang Duan, Yu-Quan Wei.   

Abstract

Heme oxygenase-1 [HO-1, also called heat shot protein 32 (HSP32)] can specifically metabolize heme to carbon monoxide, biliverdin, and ferrous iron and plays an important role in the processes of anti-inflammation, tissue protection, and antioxidative stress reaction. It has been reported that HO-1 can promote tumorigenesis and metastasis of many tumors. However, the detailed mechanisms of how HO-1 affects tumor progress are not clear. Here, we used ZnPPIX (a specific inhibitor of HO-1) to evaluate its potential effects on mouse breast cancer and tumor-associated macrophages (TAMs). We found out that mouse 4T1 breast cancer growth can be effectively suppressed through inhibition of HO-1 in vitro and in vivo. Moreover, in the 4T1 mouse model, when HO-1 was suppressed in TAMs, alternatively activated macrophages (M2 type) switched to classically activated macrophages (M1 type). In conclusion, 4T1 breast cancer growth was modulated by HO-1 expression. Furthermore, inhibition of HO-1 may induce tumor-associated immune response by activating TAMs' alternative proliferation. These data suggest that HO-1 may be an important target of breast cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24308158     DOI: 10.3727/096504013x13715991125684

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  15 in total

1.  An obligatory anaerobic Salmonella typhimurium strain redirects M2 macrophages to the M1 phenotype.

Authors:  Mei Yang; Juan Xu; Qi Wang; An-Qin Zhang; Kun Wang
Journal:  Oncol Lett       Date:  2018-01-08       Impact factor: 2.967

Review 2.  Gasotransmitters in cancer: from pathophysiology to experimental therapy.

Authors:  Csaba Szabo
Journal:  Nat Rev Drug Discov       Date:  2015-12-18       Impact factor: 84.694

3.  Cytotoxic T lymphocytes promote cytarabine-induced acute myeloid leukemia cell apoptosis via inhibiting Bcl-2 expression.

Authors:  Rui Deng; Fang-Yi Fan; Hai Yi; Li Fu; Yan Zeng; Yi Wang; Xiao-Juan Miao; Yan-Rong Shuai; Guang-Cui He; Yi Su
Journal:  Exp Ther Med       Date:  2017-06-16       Impact factor: 2.447

Review 4.  HO-1 Induction in Cancer Progression: A Matter of Cell Adaptation.

Authors:  Mariapaola Nitti; Sabrina Piras; Umberto M Marinari; Lorenzo Moretta; Maria A Pronzato; Anna Lisa Furfaro
Journal:  Antioxidants (Basel)       Date:  2017-05-05

Review 5.  Regulation of Immune Cell Functions by Metabolic Reprogramming.

Authors:  Jaehong Kim
Journal:  J Immunol Res       Date:  2018-02-13       Impact factor: 4.818

Review 6.  Heme oxygenase inhibition in cancers: possible tools and targets.

Authors:  Paulina Podkalicka; Olga Mucha; Alicja Józkowicz; Józef Dulak; Agnieszka Łoboda
Journal:  Contemp Oncol (Pozn)       Date:  2018-03-05

Review 7.  Role of Tumor-Associated Myeloid Cells in Breast Cancer.

Authors:  Yoon Jin Cha; Ja Seung Koo
Journal:  Cells       Date:  2020-07-27       Impact factor: 6.600

Review 8.  Clinical Significance of Heme Oxygenase 1 in Tumor Progression.

Authors:  Mariapaola Nitti; Caterina Ivaldo; Nicola Traverso; Anna Lisa Furfaro
Journal:  Antioxidants (Basel)       Date:  2021-05-17

9.  Heme oxygenase-1 in macrophages controls prostate cancer progression.

Authors:  Zsuzsanna Nemeth; Mailin Li; Eva Csizmadia; Balazs Döme; Martin Johansson; Jenny Liao Persson; Pankaj Seth; Leo Otterbein; Barbara Wegiel
Journal:  Oncotarget       Date:  2015-10-20

10.  Extratumoral Heme Oxygenase-1 (HO-1) Expressing Macrophages Likely Promote Primary and Metastatic Prostate Tumor Growth.

Authors:  Sofia Halin Bergström; Maria Nilsson; Hanibal Adamo; Elin Thysell; Emma Jernberg; Pär Stattin; Anders Widmark; Pernilla Wikström; Anders Bergh
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.